|[February 18, 2014]
Arrowhead Announces Proposed Underwritten Offering of Common Stock
PASADENA, Calif. --(Business Wire)--
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical
company developing targeted RNAi therapeutics, today announced its
intention to offer and sell shares of its common stock in an
underwritten offering pursuant to its existing shelf registration
statement. All of the shares in the proposed offering are to be sold by
Jefferies LLC, Barclays Capital Inc. and Deutsche Bank Securities Inc.
are acting as joint book-runners for the offering. Arrowhead intends to
grant the underwriters a 30-day option to purchase additional shares of
its common stock. The offering is subject to market conditions, and
there can be no assurance as to whether or when the offering may be
completed, or the actual size or terms of the offering.
The securities described above are being offered pursuant to a shelf
registration statement (File No. 333-193748), which was declared
effective by the United States Securities and Exchange Commission
("SEC (News - Alert)") on February 12, 2014.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such jurisdiction. The
offering can be made only by means of a prospectus supplement and
accompanying prospectus, copies of which may be obtained at the SEC's
website at www.sec.gov,
or by request at Jefferies LLC, 520 Madison Avenue, 12th Floor, New
York, NY 10022, Attention: Prospectus Department, or by email to Prospectus_Department@Jefferies.com;
or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY, 11717, Telephone: (888) 603-5847, email: firstname.lastname@example.org;
or Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall
Street, New York, NY 10005-2836 or by telephone at: (800) 503-4611, or
by email at: prospectus.CPDG@db.com.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary
drug delivery technologies to develop targeted drugs based on the RNA
interference mechanism that efficiently silence disease-causing genes.
Arrowhead technologies also enable partners to create peptide-drug
conjugates that specifically home to cell types of interest while
sparing off-target tissues. Arrowhead's pipeline includes clinical
programs in chronic hepatitis B virus and obesity and partner-based
programs in oncology.
[ Back To TMCnet.com's Homepage ]